key: cord-0260299-s8uifhwj
authors: Suntronwong, N.; Yorsaeng, R.; Puenpa, J.; Auphimai, C.; Thongmee, T.; Vichaiwattana, P.; Kanokudom, S.; Duangchinda, T.; Chantima, W.; Pakchotanon, P.; Assawakosri, S.; Nilyanimit, P.; Klinfueng, S.; Wongsrisang, L.; Srimuan, D.; Thatsanatorn, T.; Sudhinaraset, N.; Wanlapakorn, N.; Poovorawan, Y.
title: COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicron
date: 2022-01-18
journal: nan
DOI: 10.1101/2022.01.17.22269415
sha: 48d28d27c134e2696b65462a7c9064a1a96c145a
doc_id: 260299
cord_uid: s8uifhwj

The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants and the waning of immunity in vaccinated individuals is resulting in increased numbers of SARS-CoV-2 breakthrough infections. This study investigated binding antibody responses and neutralizing activities against SARS-CoV-2 variants in patients with COVID 19 who had been fully vaccinated with CoronaVac (n = 78), individuals who had been fully vaccinated with CoronaVac but had not contracted COVID-19 (n = 170), and individuals who had received AZD1222 as a third vaccination (n = 210). Breakthrough infection was generally detected approximately 88 days after the second CoronaVac vaccination (interquartile range 68 to 100) days. Blood samples were collected at median of 34 days after infection. Binding antibody levels in sera from patients with breakthrough infection were significantly higher than those in individuals who had received AZD1222 as a third vaccination. However, neutralizing activities against wild-type and variants including alpha (B.1.1.7), beta (B.1.351), and delta (B.1.617.2) were comparable in patients with breakthrough infections and individuals who received a third vaccination with AZD1222, which activities are exceeding 90%. Omicron (B.1.1.529) was neutralized less effectively by serum from breakthrough infection patients, with a 6.3-fold reduction compared to delta variants. The study suggests that breakthrough infection after two doses of an inactivated vaccine can induce neutralizing antibody against omicron. Further investigation is needed to assess the long term persistence of antibody against omicron variant.

. Vaccines are an 29 available tool to prevent and control this threat. Reduced viral susceptibility to 30 vaccine-induced antibodies due to the emergence of severe acute respiratory syndrome 31 coronavirus 2 (SARS-CoV-2) variants, together with the waning of vaccine-induced 32 immunity, is increasing the incidence of COVID-19 breakthrough infection after 33 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in during the study period were alpha (April to June) and delta (July to September) ( Figure 1 ). 45

Controls were unexposed SARS-CoV-2 individuals who had been fully vaccinated with two 46 doses of CoronaVac and screened with anti-nucleocapsid IgG as previously described [5] . 47

Fully vaccinated CoronaVac individuals who received AZD1222 as a third vaccination were 48 also analysed [6] . Table 2 ). Neutralizing 97 activities in breakthrough infection patients were significantly higher than those in unexposed 98 individuals following complete CoronaVac vaccination (p < 0.001) ( Figure 1D-G) . 99

Compared to individuals who received AZD1222 as a third vaccination, in patients with 100 breakthrough infection neutralizing activity was significantly higher for alpha (p = 0.02) and 101 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 18, 2022. ; https://doi.org/10.1101/2022.01.17.22269415 doi: medRxiv preprint beta (p < 0.01) variants, but not wild-type or delta variants. This suggests that variant cross-102 neutralization was improved after breakthrough infection. With respect to neutralizing 103 antibody titres in sera from patients with breakthrough infection determined using live virus 104 neutralization test, FRNT50, the geometric mean titres against delta were 1332 (95% CI 875-105 2026), whereas those against omicron were 212 (95% CI 142-316) ( Figure 1H ). This 106 indicates that omicron is less effectively neutralized by serum antibody derived from 107 breakthrough infection, with a 6.3-fold reduction compared to delta (p < 0.001). with breakthrough infection in the present study also exhibited less neutralizing activity 123 against omicron than against delta. Consistent with a previous study [4] neutralization against 124 omicron was 11.7-fold less than that for wild-type, and 7.9-fold less than that for delta. These 125 results suggest immune escape of omicron in breakthrough infection patients. Reduced 126 neutralizing potency against the omicron variant may be associated with many mutations in 127 the spike protein [13] . 128

The limitations of this study include a small sample size, and the SARS-CoV-2 variants 129 that caused breakthrough infections were not identified. Omicron neutralization assays were 130 not conducted using sera from unexposed individuals who had been fully vaccinated with two 131 doses of CoronaVac or those who received AZD1222 as a third vaccination. Our finding 132 highlights that breakthrough infection after two doses of inactivated vaccines can induce 133 neutralizing antibody against omicron. Further investigation is needed to assess the long-term 134 persistence of antibody against omicron variant. 135 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

World Health Organization. WHO Coronavirus (COVID-19) Dashboard

Correlation of SARS-CoV-2-breakthrough 155 infections to time-from-vaccine

Covid-19 breakthrough infections in vaccinated 157 health care workers

Omicron variant showed lower neutralizing sensitivity than 159 other SARS-CoV-2 variants to immune sera elicited by vaccines after boost

Safety and 162 immunogenicity of heterologous and homologous inactivated and adenoviral

COVID-19 vaccines in healthy adults

Immunogenicity of a third 165 dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in 166 healthy adults

Reduced neutralization of SARS-CoV-2 B.1.1.7 168 variant by convalescent and vaccine sera

Correlates of protection against symptomatic and 170 asymptomatic SARS-CoV-2 infection

Antibody response and variant cross-172 neutralization after SARS-CoV-2 breakthrough infection

mRNA vaccination boosts cross-variant 175 neutralizing antibodies elicited by SARS-CoV-2 infection

Increased risk of SARS-CoV-2 178

reinfection associated with emergence of the Omicron variant in South Africa. medRxiv

SARS-CoV-2 B. 1.1. 529 variant (Omicron

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 18, 2022. ; https://doi.org/10.1101/2022.01.17.22269415 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in correction.*p < 0.05, **p < 0.01, ***p < 0.001. 201 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 18, 2022. ; https://doi.org/10.1101/2022.01.17.22269415 doi: medRxiv preprint